Redx Pharma has a total of 670 patents globally, out of which 245 have been granted. Of these 670 patents, 45.22% patents are active. United Kingdom is where Redx Pharma has filed the maximum number of patents, followed by United States of America and Europe (EPO). Parallelly, United Kingdom seems to be the main focused R&D centre and also is the origin country of Redx Pharma.
Founded in 2010, Redx Pharma is a clinical-stage biotechnology company focused on discovering and developing novel small-molecule therapeutics for diseases with significant unmet medical needs. The company specializes in fibrosis and oncology, leveraging its expertise in medicinal chemistry and drug discovery to advance innovative therapies. Redx Pharma is committed to developing differentiated treatments that address challenging diseases and improve patient outcomes.
In August 2026, Skye Bioscience and Redx Pharma announced a definitive agreement to merge, marking a strategic shift toward fibrosis and strengthening their capabilities in developing innovative therapies for fibrotic diseases. The transaction will combine Redx’s clinical-stage pipeline, including RXC008 for fibrostenotic Crohn’s disease, with Skye’s public-market platform and approximately $125 million in committed financing. The combined company is expected to operate as Fibrx Therapeutics and trade on Nasdaq, with the transaction expected to close in Q4 2026.
Do read about some of the most notable patents of Redx Pharma covered in this article. You can also explore Redx Pharma’ patent portfolio, worldwide patent filing activity, patent filing trends over the years, and many other statistics related to its patent portfolio.
How many patents does Redx Pharma have?
Redx Pharma has a total of 670 patents globally. These patents belong to 120 unique patent families. Out of 670 patents, 303 patents are active.
How Many Patents did Redx Pharma File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Redx Pharma Applications Filed | Redx Pharma Patents Granted |
| 2026 | 1 | 7 |
| 2025 | 22 | 20 |
| 2024 | 34 | 7 |
| 2023 | 69 | 13 |
| 2022 | 67 | 29 |
| 2021 | 5 | 6 |
| 2020 | 7 | 14 |
| 2019 | 31 | 18 |
| 2018 | 4 | 12 |
| 2017 | 34 | 17 |
Redx Pharma’s Patent Focus Is Shifting Toward ROCK and DDR Technologies
A closer look at Redx Pharma’s patent families reveals a noticeable evolution in its technology focus. Earlier portfolio expansion included significant activity around WNT-signaling inhibitors, with WNT-related families accounting for around 75 patent records. More recent filings, however, show growing emphasis on Rho-associated protein kinase (ROCK) and DDR1/DDR2 inhibitors.
This shift is particularly visible in newer patent families. A 2022 ROCK inhibitor family alone includes 36 records across 32 countries, while the DDR1- and DDR2-related families identified in the portfolio are concentrated mainly in 2021-2023 priority years. The pattern indicates that Redx is progressively building its newer IP position around ROCK and DDR-targeted drug programs while maintaining protection around selected earlier WNT technologies.
How many Redx Pharma patents are Alive/Dead?
How Many Patents did Redx Pharma File in Different Countries?
Countries in which Redx Pharma Filed Patents
| Country | Patent |
| United Kingdom | 128 |
| United States of America | 42 |
| Europe (EPO) | 35 |
| Canada | 27 |
| Japan | 27 |
| Australia | 26 |
| Mexico | 22 |
| Israel | 22 |
| India | 22 |
| Singapore | 21 |
| Brazil | 21 |
| China | 21 |
| Hong Kong (S.A.R.) | 15 |
| Germany | 14 |
| South Africa | 13 |
| Austria | 11 |
| New Zealand | 11 |
| Eurasia | 11 |
| Spain | 10 |
| Denmark | 10 |
| Poland | 10 |
| Indonesia | 10 |
| Philippines | 9 |
| Portugal | 8 |
| Hungary | 8 |
| Korea (South) | 8 |
| Italy | 8 |
| Slovenia | 6 |
| Norway | 6 |
| Cyprus | 5 |
| Turkey | 5 |
| Croatia | 5 |
| Lithuania | 5 |
| Albania | 4 |
| Malta | 4 |
| Estonia | 4 |
| Slovakia | 3 |
| Serbia | 2 |
| Finland | 1 |
Track Every Patent Move in Real Time Across 70+ Jurisdictions with Elixir
Where are Research Centres of Redx Pharma Patents Located?
10 Best Redx Pharma Patents
WO2014188173A1 is the most popular patent in the Redx Pharma portfolio. It has received 108 citations so far from companies like, Arqule, Inc. and Pfizer Inc.
Below is the list of 10 most cited patents of Redx Pharma:
| Publication Number | Citation Count |
| WO2014188173A1 | 108 |
| WO2017001853A1 | 107 |
| WO2022258974A1 | 56 |
| WO2016059412A1 | 54 |
| WO2015189620A1 | 53 |
| WO2015140566A1 | 47 |
| GB2515785A | 43 |
| WO2016051181A1 | 38 |
| WO2016051193A1 | 34 |
| WO2016055786A1 | 25 |
What Percentage of Redx Pharma US Patent Applications Were Granted?
Redx Pharma (Excluding its subsidiaries) has filed 55 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 38 have been granted leading to a grant rate of 88.37%.
Below are the key stats of Redx Pharma patent prosecution at the USPTO.
Which Law Firms are managing US Patents for Redx Pharma?
| Law Firm | Total Applications | Success Rate |
| Foley Hoag Llp | 24 | 88.24% |
| Cooley Llp | 6 | 100.00% |
| Greenberg Traurig Llp | 5 | 60.00% |
| Morgan Lewis & Bockius Llp | 3 | 66.67% |
| Myers Bigel Pa | 3 | 100.00% |
| Dinsmore & Shohl Llp | 2 | 100.00% |
| Faegre Drinker Biddle & Reath Llp | 1 | 0% |
What are Redx Pharma key innovation segments?
What Technologies are Covered by Redx Pharma?
The chart below distributes patents filed by Redx Pharma